Amyloid beta: structure, biology and structure-based therapeutic development
暂无分享,去创建一个
Karsten Melcher | Yi Jiang | H. Xu | Yi Jiang | K. Melcher | H Eric Xu | Guo-fang Chen | Ting-hai Xu | Yan Yan | Yu-ren Zhou | Yan Yan | Ting-Hai Xu | Yu-ren Zhou | Guoqiang Chen | H. E. Xu | XU HEric
[1] Helen Y. Lee,et al. Adherence to Antiretroviral Therapy in Managed Care Members in the United States: A Retrospective Claims Analysis , 2014, Journal of managed care pharmacy : JMCP.
[2] G. Bu,et al. Lipoprotein receptors and cholesterol in APP trafficking and proteolytic processing, implications for Alzheimer's disease. , 2009, Seminars in cell & developmental biology.
[3] J. Dordick,et al. Aromatic Small Molecules Remodel Toxic Soluble Oligomers of Amyloid β through Three Independent Pathways* , 2010, The Journal of Biological Chemistry.
[4] T. Iwatsubo,et al. Neprilysin Degrades Both Amyloid β Peptides 1–40 and 1–42 Most Rapidly and Efficiently among Thiorphan- and Phosphoramidon-sensitive Endopeptidases* , 2001, The Journal of Biological Chemistry.
[5] Yan Sun,et al. Mutation screening and association study of the neprilysin gene in sporadic Alzheimer's disease in Chinese persons. , 2005, The journals of gerontology. Series A, Biological sciences and medical sciences.
[6] A. Giese,et al. Inhibition and disaggregation of α‐synuclein oligomers by natural polyphenolic compounds , 2011, FEBS letters.
[7] Peter J. Lenting,et al. LRP/Amyloid β-Peptide Interaction Mediates Differential Brain Efflux of Aβ Isoforms , 2004, Neuron.
[8] Andrew S. Felts. Molecule of the Month. , 2008, Drug news & perspectives.
[9] Hoau Yan Wang,et al. Amyloid Peptide Aβ1‐42 Binds Selectively and with Picomolar Affinity to α7 Nicotinic Acetylcholine Receptors , 2000 .
[10] C. Soto. Alzheimer’s and prion disease as disorders of protein conformation: implications for the design of novel therapeutic approaches , 1999, Journal of Molecular Medicine.
[11] M. Higuchi,et al. Metabolism of amyloid-β peptide and Alzheimer's disease , 2005 .
[12] S. Haeberlein,et al. AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics , 2016, Journal of Alzheimer's disease : JAD.
[13] Christos Boutsidis,et al. Atomic-level characterization of the ensemble of the Aβ(1-42) monomer in water using unbiased molecular dynamics simulations and spectral algorithms. , 2011, Journal of molecular biology.
[14] D. Holtzman,et al. Apolipoprotein E, amyloid, and Alzheimer disease. , 2002, Molecular interventions.
[15] Jean-Claude Martinou,et al. Nitric oxide‐induced mitochondrial fission is regulated by dynamin‐related GTPases in neurons , 2006, The EMBO journal.
[16] D. Salmon,et al. Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment , 1991, Annals of neurology.
[17] N. Thomson,et al. Effect of inhaled thiorphan, a neutral endopeptidase inhibitor, on the bronchodilator response to inhaled atrial natriuretic peptide (ANP). , 1996, Thorax.
[18] Holtzman,et al. Clearance of amyloid beta-peptide from brain: transport or metabolism? , 2000, Nature medicine.
[19] H. Kretzschmar,et al. Synapse Formation and Function Is Modulated by the Amyloid Precursor Protein , 2006, The Journal of Neuroscience.
[20] G. Glenner,et al. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. , 1984, Biochemical and biophysical research communications.
[21] G Klopman,et al. Solution structure of residues 1-28 of the amyloid beta-peptide. , 1994, Biochemistry.
[22] G. Schellenberg,et al. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. , 2008, Journal of Alzheimer's disease : JAD.
[23] D. Holtzman. Role of apoe/Abeta interactions in the pathogenesis of Alzheimer's disease and cerebral amyloid angiopathy. , 2001, Journal of molecular neuroscience : MN.
[24] Pritam Das,et al. NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo , 2003 .
[25] C. Masters,et al. Metal Ions, pH, and Cholesterol Regulate the Interactions of Alzheimer's Disease Amyloid-β Peptide with Membrane Lipid* , 2003, The Journal of Biological Chemistry.
[26] B. Ray,et al. Autism, Alzheimer disease, and fragile X , 2011, Neurology.
[27] G. Wenk,et al. Neuropathologic changes in Alzheimer's disease. , 2003, The Journal of clinical psychiatry.
[28] T. Saido,et al. Identification of the major Aβ1–42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition , 2000, Nature Medicine.
[29] J. Hardy,et al. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. , 1991, Trends in pharmacological sciences.
[30] R. Nixon,et al. Properties of the endosomal-lysosomal system in the human central nervous system: disturbances mark most neurons in populations at risk to degenerate in Alzheimer's disease , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[31] M. Mattson. Pathways towards and away from Alzheimer's disease , 2004, Nature.
[32] J. Fantini,et al. Bexarotene blocks calcium-permeable ion channels formed by neurotoxic Alzheimer's β-amyloid peptides. , 2014, ACS chemical neuroscience.
[33] Julien Rossignol,et al. A comparative study of dietary curcumin, nanocurcumin, and other classical amyloid-binding dyes for labeling and imaging of amyloid plaques in brain tissue of 5×-familial Alzheimer’s disease mice , 2016, Histochemistry and Cell Biology.
[34] R. Deane,et al. Method for measurement of the blood–brain barrier permeability in the perfused mouse brain: application to amyloid-β peptide in wild type and Alzheimer’s Tg2576 mice , 2004, Journal of Neuroscience Methods.
[35] M. Higuchi,et al. Fluoro-substituted and 13C-labeled styrylbenzene derivatives for detecting brain amyloid plaques. , 2004, European journal of medicinal chemistry.
[36] Kaixian Chen,et al. Novel anti-Alzheimer’s dimer bis(7)-Cognitin: Cellular and molecular mechanisms of neuroprotection through multiple targets , 2011, Neurotherapeutics.
[37] F. Visioli,et al. Antioxidant and other biological activities of phenols from olives and olive oil , 2002, Medicinal research reviews.
[38] K. Beyreuther,et al. What the evolution of the amyloid protein precursor supergene family tells us about its function , 2000, Neurochemistry International.
[39] A. Jones,et al. Physical basis of colors seen in Congo red-stained amyloid in polarized light , 2008, Laboratory Investigation.
[40] B Frangione,et al. Inhibition of Alzheimer beta-fibrillogenesis by melatonin. , 1998, The Journal of biological chemistry.
[41] D. Butterfield,et al. Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. , 2000, Journal of structural biology.
[42] M. Mattson,et al. Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.
[43] R. Tanzi,et al. Alzheimer's disease: one disorder, too many genes? , 2004, Human molecular genetics.
[44] G. Wilcock,et al. The cholinergic hypothesis of Alzheimer’s disease: a review of progress , 1999, Journal of neurology, neurosurgery, and psychiatry.
[45] G. Bloom. Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis. , 2014, JAMA neurology.
[46] T. Saido,et al. Metabolic regulation of brain Abeta by neprilysin. , 2001, Science.
[47] F. Crawford,et al. Inhibition of Alzheimer's β-Amyloid Induced Vasoactivity and Proinflammatory Response in Microglia by a cGMP-Dependent Mechanism , 1999, Experimental Neurology.
[48] Roger N Rosenberg,et al. Genome-wide association studies in Alzheimer disease. , 2008, Archives of neurology.
[49] J. D. Figueroa-Villar,et al. Targeting the neurotoxic species in Alzheimer's disease: inhibitors of Aβ oligomerization , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[50] T. Iwatsubo,et al. The role of presenilin cofactors in the gamma-secretase complex. , 2003, Nature.
[51] D. Teplow,et al. Amyloid beta-peptide is produced by cultured cells during normal metabolism. , 1992, Nature.
[52] N. Robakis. Mechanisms of AD neurodegeneration may be independent of Aβ and its derivatives , 2011, Neurobiology of Aging.
[53] D. Selkoe,et al. Passage of human amyloid β-protein 1–40 across the murine blood-brain barrier , 1994 .
[54] Yong Shen,et al. Alzheimer's disease-like pathological features in transgenic mice expressing the APP intracellular domain , 2009, Proceedings of the National Academy of Sciences.
[55] H. Qing,et al. Potential Therapeutic Strategies for Alzheimer's Disease Targeting or Beyond β-Amyloid: Insights from Clinical Trials , 2014, BioMed research international.
[56] Wei Xu,et al. aph-1 and pen-2 Are Required for Notch Pathway Signaling, γ-Secretase Cleavage of βAPP, and Presenilin Protein Accumulation , 2002 .
[57] T. Saido,et al. Biochemical identification of the neutral endopeptidase family member responsible for the catabolism of amyloid beta peptide in the brain. , 2000, Journal of biochemistry.
[58] Junying Yuan,et al. FcγRIIb mediates amyloid-β neurotoxicity and memory impairment in Alzheimer's disease. , 2013, The Journal of clinical investigation.
[59] A. Schmidt,et al. Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes , 2002, Ageing Research Reviews.
[60] S. Müller,et al. Multiple assembly pathways underlie amyloid-beta fibril polymorphisms. , 2005, Journal of molecular biology.
[61] W. Duckworth,et al. Insulin acts intracellularly on proteasomes through insulin-degrading enzyme. , 1998, Biochemical and biophysical research communications.
[62] C. Combs,et al. Beta amyloid oligomers and fibrils stimulate differential activation of primary microglia , 2009, Journal of Neuroinflammation.
[63] A. Mazur,et al. Structural Changes of Region 1-16 of the Alzheimer Disease Amyloid β-Peptide upon Zinc Binding and in Vitro Aging* , 2006, Journal of Biological Chemistry.
[64] S A Small,et al. Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease. , 1999, Annals of neurology.
[65] S. Scheff,et al. The Plasmin System Is Induced by and Degrades Amyloid-β Aggregates , 2000, The Journal of Neuroscience.
[66] R. Segurado,et al. NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease , 2014, BMJ Open.
[67] C. Barbato,et al. MicroRNA-101 Regulates Amyloid Precursor Protein Expression in Hippocampal Neurons* , 2010, The Journal of Biological Chemistry.
[68] M. Mattson,et al. Amyloid beta-peptide impairs ion-motive ATPase activities: evidence for a role in loss of neuronal Ca2+ homeostasis and cell death , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[69] R. Nitsch,et al. The APP intracellular domain forms nuclear multiprotein complexes and regulates the transcription of its own precursor , 2004, Journal of Cell Science.
[70] M. Ball,et al. Proteolysis of Aβ Peptide from Alzheimer Disease Brain by Gelatinase A , 1994 .
[71] R A Crowther,et al. Tau Proteins and Neurofibrillary Degeneration , 1991, Brain pathology.
[72] C. Reitz. Dyslipidemia and the Risk of Alzheimer’s Disease , 2013, Current Atherosclerosis Reports.
[73] N. Mercuri,et al. Profile of gantenerumab and its potential in the treatment of Alzheimer’s disease , 2013, Drug design, development and therapy.
[74] Richard D. Leapman,et al. Self-Propagating, Molecular-Level Polymorphism in Alzheimer's ß-Amyloid Fibrils , 2005, Science.
[75] A. Bruno,et al. Human membrane metallo-endopeptidase-like protein degrades both beta-amyloid 42 and beta-amyloid 40 , 2008, Neuroscience.
[76] D. Selkoe. Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.
[77] M. Riepe,et al. Adding memantine to rivastigmine therapy in patients with mild-to-moderate alzheimer's disease: results of a 12-week, open-label pilot study. , 2006, Primary care companion to the Journal of clinical psychiatry.
[78] T. Benzinger,et al. Propagating structure of Alzheimer’s β-amyloid(10–35) is parallel β-sheet with residues in exact register , 1998 .
[79] P. Brachet,et al. 1,25-Dihydroxyvitamin D3 regulates the expression of the low-affinity neurotrophin receptor. , 1996, Brain research. Molecular brain research.
[80] J. Egido,et al. Immunoglobulin G Fc receptor deficiency prevents Alzheimer-like pathology and cognitive impairment in mice. , 2012, Brain : a journal of neurology.
[81] G. Glenner,et al. Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein , 1984 .
[82] D. Selkoe,et al. Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide. , 1993, Cell.
[83] M. Staufenbiel,et al. Neprilysin-sensitive Synapse-associated Amyloid-β Peptide Oligomers Impair Neuronal Plasticity and Cognitive Function* , 2006, Journal of Biological Chemistry.
[84] A. Scaloni,et al. Acyl peptide hydrolase, a serine proteinase isolated from conditioned medium of neuroblastoma cells, degrades the amyloid‐β peptide , 2007, Journal of neurochemistry.
[85] H. You,et al. Implication of the small GTPase Rac1 in the generation of reactive oxygen species in response to beta-amyloid in C6 astroglioma cells. , 2002, The Biochemical journal.
[86] Z. Shen,et al. Brain cholinesterases: II. The molecular and cellular basis of Alzheimer's disease. , 2004, Medical hypotheses.
[87] C. Finch,et al. Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum? , 2001, Trends in Neurosciences.
[88] M. Pericak-Vance,et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[89] J. Clarimón,et al. Autosomal‐dominant Alzheimer's disease mutations at the same codon of amyloid precursor protein differentially alter Aβ production , 2014, Journal of neurochemistry.
[90] P. Lansbury,et al. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. , 2002, Journal of molecular biology.
[91] M. Mercken,et al. Presenilin Redistribution Associated with Aberrant Cholesterol Transport Enhances β-Amyloid Production In Vivo , 2003, The Journal of Neuroscience.
[92] Wenming Li,et al. Cdk5: Mediator of neuronal development, death and the response to DNA damage , 2011, Mechanisms of Ageing and Development.
[93] C. B. Davis,et al. Amyloid peptide Abeta(1-42) binds selectively and with picomolar affinity to alpha7 nicotinic acetylcholine receptors. , 2000, Journal of neurochemistry.
[94] K. Blennow,et al. Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study , 2012, The Lancet Neurology.
[95] W. V. Van Nostrand,et al. Plasmin cleavage of the amyloid beta-protein: alteration of secondary structure and stimulation of tissue plasminogen activator activity. , 1999, Biochemistry.
[96] C. Haass,et al. Insulin-degrading Enzyme Rapidly Removes the β-Amyloid Precursor Protein Intracellular Domain (AICD)* , 2002, The Journal of Biological Chemistry.
[97] H. Koeppen,et al. Human plasma contains cross-reactive Abeta conformer-specific IgG antibodies. , 2008, Biochemistry.
[98] Yoshitaka Ishii,et al. Constraints on supramolecular structure in amyloid fibrils from two-dimensional solid-state NMR spectroscopy with uniform isotopic labeling. , 2003, Journal of the American Chemical Society.
[99] Hualiang Jiang,et al. Quantitative proteomic analysis reveals the neuroprotective effects of huperzine A for amyloid beta treated neuroblastoma N2a cells , 2013, Proteomics.
[100] D. Holtzman,et al. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[101] G. Perini,et al. Role of p75 Neurotrophin Receptor in the Neurotoxicity by β-amyloid Peptides and Synergistic Effect of Inflammatory Cytokines , 2002, The Journal of experimental medicine.
[102] Bradley T. Hyman,et al. Human LilrB2 Is a β-Amyloid Receptor and Its Murine Homolog PirB Regulates Synaptic Plasticity in an Alzheimer’s Model , 2013, Science.
[103] Xudong Huang,et al. Characterization of copper interactions with alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta1-42. , 2008, Journal of neurochemistry.
[104] M. Heneka,et al. Innate immunity in Alzheimer's disease , 2015, Nature Immunology.
[105] E. Rojas,et al. Giant multilevel cation channels formed by Alzheimer disease amyloid beta-protein [A beta P-(1-40)] in bilayer membranes. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[106] Michael J. Rowan,et al. Amyloid-β oligomers: their production, toxicity and therapeutic inhibition , 2001 .
[107] L. Mucke,et al. Antiamyloidogenic and Neuroprotective Functions of Cathepsin B: Implications for Alzheimer's Disease , 2006, Neuron.
[108] Rong Wang,et al. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity , 2001, Nature.
[109] T. Iwatsubo,et al. The role of presenilin cofactors in the γ-secretase complex , 2003, Nature.
[110] R. Tanzi,et al. Clearance of Alzheimer's Abeta peptide: the many roads to perdition. , 2004, Neuron.
[111] E. Gazit,et al. Naphthoquinone-tyrptophan reduces neurotoxic Aβ*56 levels and improves cognition in Alzheimer's disease animal model , 2012, Neurobiology of Disease.
[112] C. Masters,et al. Alzheimer's Disease Amyloid-β Binds Copper and Zinc to Generate an Allosterically Ordered Membrane-penetrating Structure Containing Superoxide Dismutase-like Subunits* , 2001, The Journal of Biological Chemistry.
[113] D. Teplow,et al. Amyloid β-protein oligomers and Alzheimer’s disease , 2013, Alzheimer's Research & Therapy.
[114] E. Masliah,et al. Cortical and subcortical patterns of synaptophysinlike immunoreactivity in Alzheimer's disease. , 1991, The American journal of pathology.
[115] U. Lendahl,et al. Characterization of Intermediate Steps in Amyloid Beta (Aβ) Production under Near-native Conditions* , 2013, The Journal of Biological Chemistry.
[116] Martin Ingelsson,et al. The Alzheimer's Disease-Associated Amyloid \(\beta\)-Protein Is an Antimicrobial Peptide , 2010 .
[117] Carl W. Cotman,et al. Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.
[118] G. Bormans,et al. 99mTc-MAMA-chrysamine G, a probe for beta-amyloid protein of Alzheimer’s disease , 1999, European Journal of Nuclear Medicine.
[119] K. Iwata,et al. The Alzheimer's peptide a beta adopts a collapsed coil structure in water. , 2000, Journal of structural biology.
[120] R. Leapman,et al. Supramolecular structural constraints on Alzheimer's beta-amyloid fibrils from electron microscopy and solid-state nuclear magnetic resonance. , 2002, Biochemistry.
[121] R. Deane,et al. RAGE (Yin) Versus LRP (Yang) Balance Regulates Alzheimer Amyloid &bgr;-Peptide Clearance Through Transport Across the Blood–Brain Barrier , 2004, Stroke.
[122] J. Rudd,et al. The Recent Updates of Therapeutic Approaches Against Aβ for the Treatment of Alzheimer's Disease , 2011, Anatomical record.
[123] Jakub Jończyk,et al. Therapeutic strategies for Alzheimer’s disease in clinical trials , 2016, Pharmacological reports : PR.
[124] F. Bordi,et al. Group I metabotropic glutamate receptors: implications for brain diseases , 1999, Progress in Neurobiology.
[125] C. Glabe,et al. Surfactant properties of Alzheimer's A beta peptides and the mechanism of amyloid aggregation. , 1994, The Journal of biological chemistry.
[126] Hualiang Jiang,et al. Progress in clinical, pharmacological, chemical and structural biological studies of huperzine A: a drug of traditional chinese medicine origin for the treatment of Alzheimer's disease. , 2003, Current medicinal chemistry.
[127] P. Hammarström,et al. Spectroscopic characterization of diverse amyloid fibrils in vitro by the fluorescent dye Nile red. , 2011, Molecular bioSystems.
[128] R. Wetzel,et al. Enhanced correction methods for hydrogen exchange‐mass spectrometric studies of amyloid fibrils , 2003, Protein science : a publication of the Protein Society.
[129] John Hardy,et al. Amyloid, the presenilins and Alzheimer's disease , 1997, Trends in Neurosciences.
[130] R. Leapman,et al. A structural model for Alzheimer's β-amyloid fibrils based on experimental constraints from solid state NMR , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[131] L. Marlow,et al. Alzheimer's Disease β-Amyloid Peptide Is Increased in Mice Deficient in Endothelin-converting Enzyme* , 2003, The Journal of Biological Chemistry.
[132] P. Lansbury,et al. Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. , 1997, Chemistry & biology.
[133] U. Armato,et al. The killing of neurons by beta-amyloid peptides, prions, and pro-inflammatory cytokines. , 2006, Italian journal of anatomy and embryology = Archivio italiano di anatomia ed embriologia.
[134] L. Hersh,et al. Amyloid-β peptide levels in brain are inversely correlated with insulysin activity levels in vivo , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[135] Michael J. Cullen,et al. Matrix Metalloproteinase-9 (MMP-9) Is Synthesized in Neurons of the Human Hippocampus and Is Capable of Degrading the Amyloid-β Peptide (1–40) , 1996, The Journal of Neuroscience.
[136] Yilin Yan,et al. The Alzheimer's peptides Abeta40 and 42 adopt distinct conformations in water: a combined MD / NMR study. , 2007, Journal of molecular biology.
[137] S. Chandra,et al. A second cytotoxic proteolytic peptide derived from amyloid β-protein precursor , 2000, Nature Medicine.
[138] M. Elghetany,et al. Methods for staining amyloid in tissues: a review. , 1988, Stain technology.
[139] Bernardo L Sabatini,et al. Natural Oligomers of the Alzheimer Amyloid-β Protein Induce Reversible Synapse Loss by Modulating an NMDA-Type Glutamate Receptor-Dependent Signaling Pathway , 2007, The Journal of Neuroscience.
[140] M. Higuchi,et al. Metabolism of amyloid-beta peptide and Alzheimer's disease. , 2005, Pharmacology & therapeutics.
[141] Michael J. Tobia,et al. Preclinical Investigation of the Functional Effects of Memantine and Memantine Combined with Galantamine or Donepezil , 2007, Neuropsychopharmacology.
[142] S. Maiti,et al. Selective destabilization of soluble amyloid beta oligomers by divalent metal ions. , 2006, Biochemical and biophysical research communications.
[143] Guy C. Brown,et al. Neuronal Death Induced by Nanomolar Amyloid β Is Mediated by Primary Phagocytosis of Neurons by Microglia* , 2011, The Journal of Biological Chemistry.
[144] M. L. de Ceballos,et al. Prevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation , 2005, The Journal of Neuroscience.
[145] Michael H. Hecht,et al. A Novel Inhibitor of Amyloid β (Aβ) Peptide Aggregation , 2012, The Journal of Biological Chemistry.
[146] D. Selkoe. Clearing the Brain's Amyloid Cobwebs , 2001, Neuron.
[147] M. Leissring,et al. Identification of BACE2 as an avid ß-amyloid-degrading protease , 2012, Molecular Neurodegeneration.
[148] S. Müller,et al. Studies on the in vitro assembly of a beta 1-40: implications for the search for a beta fibril formation inhibitors. , 2000, Journal of structural biology.
[149] Matthew P. Frosch,et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[150] H. Schoemaker,et al. Calpain inhibition prevents amyloid-β-induced neurodegeneration and associated behavioral dysfunction in rats , 2010, Neuropharmacology.
[151] Jill A. White,et al. Differential effects of oligomeric and fibrillar amyloid-β1–42 on astrocyte-mediated inflammation , 2005, Neurobiology of Disease.
[152] D. Selkoe,et al. Cellular processing of β-amyloid precursor protein and the genesis of amyloid β-peptide , 1993, Cell.
[153] D. Butterfield,et al. Alzheimer's amyloid β-peptide associated free radicals increase rat embryonic neuronal polyamine uptake and ornithine decarboxylase activity: protective effect of vitamin E , 1999, Neuroscience Letters.
[154] Martin Ezeani,et al. A New Perspective of Lysosomal Cation Channel-Dependent Homeostasis in Alzheimer’s Disease , 2016, Molecular Neurobiology.
[155] Ralf Langen,et al. Identifying Structural Features of Fibrillar Islet Amyloid Polypeptide Using Site-directed Spin Labeling* , 2004, Journal of Biological Chemistry.
[156] D. Galati,et al. Accumulation of Amyloid Precursor Protein in the Mitochondrial Import Channels of Human Alzheimer’s Disease Brain Is Associated with Mitochondrial Dysfunction , 2006, The Journal of Neuroscience.
[157] S. Müller,et al. Studies on the in Vitro Assembly of Aβ 1–40: Implications for the Search for Aβ Fibril Formation Inhibitors , 2000 .
[158] A. Fagan,et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. , 2005, The Journal of clinical investigation.
[159] Keiichi Higuchi,et al. Methods in laboratory investigation : fluroremetric examination of tissue amyloid fibrils in murine senile amyloidosis : use of the fluorescent indicator, thioflavine T , 1990 .
[160] J. Hardy,et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease , 2000, Nature.
[161] M. Davies,et al. In-situ atomic force microscopy study of beta-amyloid fibrillization. , 2000, Journal of molecular biology.
[162] Bernadette M. M. Zwaans,et al. Potential therapeutic strategies for lymphatic metastasis. , 2007, Microvascular research.
[163] S. Younkin,et al. Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.
[164] M. Desco,et al. [Resveratrol: a neuroprotective polyphenol in the Mediterranean diet]. , 2012, Revista de neurologia.
[165] M. Mattson,et al. A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[166] Cheng Luo,et al. Structural optimization and biological evaluation of substituted bisphenol A derivatives as beta-amyloid peptide aggregation inhibitors. , 2010, Journal of medicinal chemistry.
[167] Shirley Y. Lee,et al. A partially folded structure of amyloid-beta(1-40) in an aqueous environment. , 2011, Biochemical and biophysical research communications.
[168] M. C. Ellis,et al. aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation. , 2002, Developmental cell.
[169] W. V. Van Nostrand,et al. Capping of Aβ42 Oligomers by Small Molecule Inhibitors , 2014, Biochemistry.
[170] J. Bureš,et al. Specific spatial learning deficits become severe with age in β-amyloid precursor protein transgenic mice that harbor diffuse β-amyloid deposits but do not form plaques , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[171] G. Hjelmstad,et al. Potential Savings in the Cost of Caring for Alzheimer’s Disease , 2000, PharmacoEconomics.
[172] M. Mattson. Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. , 1997, Physiological reviews.
[173] M. Duchen,et al. Toxicity of Amyloid β Peptide: Tales of Calcium, Mitochondria, and Oxidative Stress , 2004, Neurochemical Research.
[174] K. Matsushima,et al. Fluorometric examination of tissue amyloid fibrils in murine senile amyloidosis: use of the fluorescent indicator, thioflavine T. , 1990, Laboratory investigation; a journal of technical methods and pathology.
[175] A. Palmeri,et al. The keystone of Alzheimer pathogenesis might be sought in Aβ physiology , 2015, Neuroscience.
[176] B. Zlokovic,et al. Human blood-brain barrier receptors for Alzheimer's amyloid-beta 1- 40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer. , 1998, The Journal of clinical investigation.
[177] J. Hoh,et al. Growth of β-amyloid(1-40) protofibrils by monomer elongation and lateral association. Characterization of distinct products by light scattering and atomic force microscopy , 2002 .
[178] C. Eckman,et al. Degradation of the Alzheimer's Amyloid β Peptide by Endothelin-converting Enzyme* , 2001, The Journal of Biological Chemistry.
[179] J. J. Balbach,et al. Supramolecular Structure in Full-Length Alzheimer's β-Amyloid Fibrils: Evidence for a Parallel β-Sheet Organization from Solid-State Nuclear Magnetic Resonance , 2002 .
[180] E. Masliah,et al. Spectrum of human immunodeficiency virus–associated neocortical damage , 1992, Annals of neurology.
[181] Gokcan Aydogan,et al. GM1 Ganglioside Inhibits β‐Amyloid Oligomerization Induced by Sphingomyelin , 2016, Angewandte Chemie.
[182] B. Hyman,et al. Neuropathological alterations in Alzheimer disease. , 2011, Cold Spring Harbor perspectives in medicine.
[183] E. Siemers,et al. Amyloid-ß-directed immunotherapy for Alzheimer's disease , 2014, Journal of internal medicine.
[184] D. Lawrence,et al. Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. , 2003, The Journal of clinical investigation.
[185] R. Mahley,et al. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[186] Ashley I. Bush,et al. The metallobiology of Alzheimer's disease , 2003, Trends in Neurosciences.
[187] L. Hong,et al. Subsite specificity of memapsin 2 (beta-secretase): implications for inhibitor design. , 2001, Biochemistry.
[188] P. Lansbury,et al. Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer's disease amyloid-beta protein. , 1997, Chemistry & biology.
[189] S. Estus,et al. Tissue Plasminogen Activator Requires Plasminogen to Modulate Amyloid‐β Neurotoxicity and Deposition , 2000, Journal of neurochemistry.
[190] Xi Chen,et al. Materials and Methods Som Text Figs. S1 and S2 Table S1 References Abad Directly Links A to Mitochondrial Toxicity in Alzheimer's Disease , 2022 .
[191] B. Hyman,et al. Gene Transfer of Human Apoe Isoforms Results in Differential Modulation of Amyloid Deposition and Neurotoxicity in Mouse Brain , 2013, Science Translational Medicine.
[192] J. Mcdermott,et al. Degradation of Alzheimer's beta-amyloid protein by human cathepsin D. , 1996, Neuroreport.
[193] D. Craik,et al. Solution structure of amyloid beta-peptide(1-40) in a water-micelle environment. Is the membrane-spanning domain where we think it is? , 1998, Biochemistry.
[194] R. Carp,et al. The Mouse Model for Scrapie , 2005 .
[195] C. Masters,et al. Overexpression of Alzheimer's Disease Amyloid-β Opposes the Age-dependent Elevations of Brain Copper and Iron* , 2002, The Journal of Biological Chemistry.
[196] J. Trojanowski,et al. Association of apolipoprotein ɛ4 allele and neuropathologic findings in patients with dementia , 2004, Acta Neuropathologica.
[197] Yanyu Zhao,et al. Three-dimensional structure of human γ-secretase , 2014, Nature.
[198] Michael V. Green,et al. PET imaging of brain with the β-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer’s disease , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[199] S. Squazzo,et al. Aggregation of Secreted Amyloid -Protein into Sodium Dodecyl Sulfate-stable Oligomers in Cell Culture (*) , 1995, The Journal of Biological Chemistry.
[200] B Frangione,et al. Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. , 2001, The American journal of pathology.
[201] Anand Viswanathan,et al. Cerebral amyloid angiopathy in the elderly , 2011, Annals of neurology.
[202] H. Möller,et al. Human antibodies against amyloid β peptide: A potential treatment for Alzheimer's disease , 2002 .
[203] T. Iwatsubo. The gamma-secretase complex: machinery for intramembrane proteolysis. , 2004, Current opinion in neurobiology.
[204] R. Metherate,et al. A Role for Synaptic Zinc in Activity-Dependent Aβ Oligomer Formation and Accumulation at Excitatory Synapses , 2009, The Journal of Neuroscience.
[205] M. D'Andrea,et al. Intracellular accumulation of beta-amyloid(1-42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer's disease. , 2002, Neuroscience.
[206] H. Wiśniewski,et al. Plasma amyloid β‐peptide 1–42 and incipient Alzheimer's disease , 1999 .
[207] D. Bredesen,et al. Molecular characterization of neurohybrid cell death induced by Alzheimer's amyloid‐β peptides via p75NTR/PLAIDD , 2004, Journal of neurochemistry.
[208] M. D'Andrea,et al. Intracellular accumulation of β-amyloid1–42 in neurons is facilitated by the α7 nicotinic acetylcholine receptor in Alzheimer’s disease , 2002, Neuroscience.
[209] D. Small,et al. Regulation of APP cleavage by α‐, β‐ and γ‐secretases , 2000 .
[210] A. D'Ursi,et al. Solution structure of the Alzheimer amyloid beta-peptide (1-42) in an apolar microenvironment. Similarity with a virus fusion domain. , 2002, European journal of biochemistry.
[211] Ling Li,et al. Role of toll-like receptor signalling in Abeta uptake and clearance. , 2006, Brain : a journal of neurology.
[212] T. Iwatsubo. The γ-secretase complex: machinery for intramembrane proteolysis , 2004, Current Opinion in Neurobiology.
[213] David A Bennett,et al. Brain amyloid-β oligomers in ageing and Alzheimer's disease. , 2013, Brain : a journal of neurology.
[214] Fabiana A. Caetano,et al. Metabotropic glutamate receptors transduce signals for neurite outgrowth after binding of the prion protein to laminili γ1 chain , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[215] Nick C Fox,et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease , 2013, Nature Genetics.
[216] L. Mucke,et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein , 1995, Nature.
[217] T. Bliss,et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice , 1999, Nature Neuroscience.
[218] Yanzhuang Wang,et al. Golgi defects enhance APP amyloidogenic processing in Alzheimer's disease , 2015, BioEssays : news and reviews in molecular, cellular and developmental biology.
[219] C. Blake,et al. From the globular to the fibrous state: protein structure and structural conversion in amyloid formation , 1998, Quarterly Reviews of Biophysics.
[220] P. Butko,et al. Inhibition of amyloid-β aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761 , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[221] I. Izquierdo,et al. Physiology of the prion protein. , 2008, Physiological reviews.
[222] Judianne Davis,et al. Structural conversion of neurotoxic amyloid-β(1–42) oligomers to fibrils , 2010, Nature Structural &Molecular Biology.
[223] J. Sweatt,et al. Loss of α7 Nicotinic Receptors Enhances β-Amyloid Oligomer Accumulation, Exacerbating Early-Stage Cognitive Decline and Septohippocampal Pathology in a Mouse Model of Alzheimer's Disease , 2010, The Journal of Neuroscience.
[224] Pritam Das,et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. , 2003, The Journal of clinical investigation.
[225] K. P. Kepp,et al. Ten Challenges of the Amyloid Hypothesis of Alzheimer's Disease. , 2016, Journal of Alzheimer's disease : JAD.
[226] L. Friedhoff,et al. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial , 1996 .
[227] J. Hardy,et al. The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .
[228] C. Prévost,et al. Structure of ring-shaped Aβ42 oligomers determined by conformational selection , 2016, Scientific Reports.
[229] D. Holtzman,et al. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. , 2000, The Journal of clinical investigation.
[230] Claudio Soto,et al. β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy , 1998, Nature Medicine.
[231] D. Michaelson,et al. ApoE4 induces Aβ42, tau, and neuronal pathology in the hippocampus of young targeted replacement apoE4 mice , 2013, Molecular Neurodegeneration.
[232] Hualiang Jiang,et al. 2,2′,4′‐Trihydroxychalcone from Glycyrrhiza glabra as a new specific BACE1 inhibitor efficiently ameliorates memory impairment in mice , 2010, Journal of neurochemistry.
[233] J P Moatti,et al. Hypertension in Diabetes Mellitus , 2008 .
[234] S. Maiti,et al. Selective destabilization of soluble amyloid β oligomers by divalent metal ions , 2006 .
[235] D. Holtzman. Role of apoE/Aβ interactions in the pathogenesis of Alzheimer’s disease and cerebral amyloid angiopathy , 2001, Journal of Molecular Neuroscience.
[236] W. Klein,et al. Aβ Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's Disease , 2007, The Journal of Neuroscience.
[237] T. Saido,et al. Metabolic Regulation of Brain Aβ by Neprilysin , 2001, Science.
[238] Li-Huei Tsai,et al. Amyloid-Independent Mechanisms in Alzheimer's Disease Pathogenesis , 2010, The Journal of Neuroscience.
[239] R. Tanzi,et al. Twenty Years of the Alzheimer’s Disease Amyloid Hypothesis: A Genetic Perspective , 2005, Cell.
[240] A. Hofman,et al. Variant of TREM2 associated with the risk of Alzheimer's disease. , 2013, The New England journal of medicine.
[241] D. Selkoe,et al. Toward a Comprehensive Theory for Alzheimer's Disease. Hypothesis: Alzheimer's Disease Is Caused by the Cerebral Accumulation and Cytotoxicity of Amyloid β‐Protein , 2000, Annals of the New York Academy of Sciences.
[242] I. Amit,et al. PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer's disease , 2016, Nature Medicine.
[243] R. Malinow,et al. The prion protein as a receptor for amyloid-β , 2010, Nature.
[244] Carl W. Cotman,et al. Exercise counteracts declining hippocampal function in aging and Alzheimer's disease , 2013, Neurobiology of Disease.
[245] R. Nicoll,et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[246] Yasuhiro Nishiyama,et al. Catalytic antibodies to amyloid beta peptide in defense against Alzheimer disease. , 2008, Autoimmunity reviews.
[247] F. Visioli,et al. Oleuropein, the bitter principle of olives, enhances nitric oxide production by mouse macrophages. , 1998, Life sciences.
[248] Roni Scherzer-Attali,et al. Generic inhibition of amyloidogenic proteins by two naphthoquinone–tryptophan hybrid molecules , 2012, Proteins.
[249] S. Love,et al. Influence of LRP-1 and apolipoprotein E on amyloid-β uptake and toxicity to cerebrovascular smooth muscle cells. , 2012, Journal of Alzheimer's disease : JAD.
[250] J. Trojanowski,et al. BACE overexpression alters the subcellular processing of APP and inhibits Aβ deposition in vivo , 2005, The Journal of cell biology.
[251] M. Robin,et al. Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's amyloid precursor protein impairs mitochondrial function in neuronal cells , 2003, The Journal of cell biology.
[252] T. Wyss-Coray,et al. Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. , 2003, Nature medicine.
[253] R. Mayeux,et al. Plasma A&bgr;40 and A&bgr;42 and Alzheimer’s disease: Relation to age, mortality, and risk , 2003 .
[254] C. Soto,et al. Inhibition of Alzheimer β-Fibrillogenesis by Melatonin* , 1998, The Journal of Biological Chemistry.
[255] P. Lansbury,et al. Mixtures of wild-type and a pathogenic (E22G) form of Abeta40 in vitro accumulate protofibrils, including amyloid pores. , 2003, Journal of molecular biology.
[256] John Hardy,et al. The genetic architecture of Alzheimer's disease: beyond APP, PSENs and APOE , 2012, Neurobiology of Aging.
[257] J. H. Viles,et al. A Comparison of Three Fluorophores for the Detection of Amyloid Fibers and Prefibrillar Oligomeric Assemblies. ThT (Thioflavin T); ANS (1-Anilinonaphthalene-8-sulfonic Acid); and bisANS (4,4'-Dianilino-1,1'-binaphthyl-5,5'-disulfonic Acid). , 2015, Biochemistry.
[258] R. Leapman,et al. Multiple quantum solid-state NMR indicates a parallel, not antiparallel, organization of β-sheets in Alzheimer's β-amyloid fibrils , 2000 .
[259] M G McInnis,et al. Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. , 2000, Science.
[260] Hualiang Jiang,et al. Arctigenin Effectively Ameliorates Memory Impairment in Alzheimer's Disease Model Mice Targeting Both β-Amyloid Production and Clearance , 2013, The Journal of Neuroscience.
[261] G. Glenner,et al. X-RAY DIFFRACTION STUDIES ON AMYLOID FILAMENTS , 1968, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[262] D. Walsh,et al. Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. , 1997, The Journal of biological chemistry.
[263] Chiou-Miin Wang,et al. Immunization with the SDPM1 peptide lowers amyloid plaque burden and improves cognitive function in the APPswePSEN1(A246E) transgenic mouse model of Alzheimer's disease , 2010, Neurobiology of Disease.
[264] Hoau Yan Wang,et al. Alpha 7 nicotinic acetylcholine receptors mediate beta-amyloid peptide-induced tau protein phosphorylation. , 2003, The Journal of biological chemistry.
[265] F. Gasparini,et al. An activity‐dependent switch from facilitation to inhibition in the control of excitotoxicity by group I metabotropic glutamate receptors , 2001, The European journal of neuroscience.
[266] Hoau Yan Wang,et al. α7 Nicotinic Acetylcholine Receptors Mediate β-Amyloid Peptide-induced Tau Protein Phosphorylation* , 2003, Journal of Biological Chemistry.
[267] Ralf Langen,et al. Template-assisted filament growth by parallel stacking of tau. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[268] R. Tanzi,et al. Amyloid-β peptide protects against microbial infection in mouse and worm models of Alzheimer’s disease , 2016, Science Translational Medicine.
[269] David J. Cummins,et al. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[270] I. Mikhailenko,et al. Beyond endocytosis: LRP function in cell migration, proliferation and vascular permeability , 2005, Journal of thrombosis and haemostasis : JTH.
[271] T. Bayer,et al. Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Aβ production in APP23 transgenic mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[272] John M. Hancock,et al. A tale of two drug targets: the evolutionary history of BACE1 and BACE2 , 2013, Front. Genet..
[273] Y. Ihara,et al. γ-Secretase: Successive Tripeptide and Tetrapeptide Release from the Transmembrane Domain of β-Carboxyl Terminal Fragment , 2009, The Journal of Neuroscience.
[274] D. Selkoe,et al. The Swedish mutation causes early-onset Alzheimer's disease by β-secretase cleavage within the secretory pathway , 1995, Nature Medicine.
[275] P. Greengard,et al. Regulation of NMDA receptor trafficking by amyloid-β , 2005, Nature Neuroscience.
[276] J. Blangero,et al. Linkage of plasma Abeta42 to a quantitative locus on chromosome 10 in late-onset Alzheimer's disease pedigrees. , 2000, Science.
[277] F. Gil-Bea,et al. Effects of 5‐HT6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat , 2008, British journal of pharmacology.
[278] A. McKee,et al. Acyl peptide hydrolase degrades monomeric and oligomeric amyloid-beta peptide , 2009, Molecular Neurodegeneration.
[279] A. Tsantili-Kakoulidou,et al. The olive constituent oleuropein exhibits anti-ischemic, antioxidative, and hypolipidemic effects in anesthetized rabbits. , 2006, The Journal of nutrition.
[280] S. Cregan,et al. Group I metabotropic glutamate receptor signalling and its implication in neurological disease. , 2010, CNS & neurological disorders drug targets.
[281] Yue-Ming Li,et al. Physiological and pathological roles of the γ-secretase complex , 2016, Brain Research Bulletin.
[282] Christian Gaser,et al. The Effect of the APOE Genotype on Individual BrainAGE in Normal Aging, Mild Cognitive Impairment, and Alzheimer’s Disease , 2016, PloS one.
[283] D. Guo,et al. Macromolecular and small-molecule modulation of intracellular Aβ42 aggregation and associated toxicity. , 2012, The Biochemical journal.
[284] C. Goldsbury,et al. Time-lapse atomic force microscopy in the characterization of amyloid-like fibril assembly and oligomeric intermediates. , 2005, Methods in molecular biology.
[285] Peter T. Lansbury,et al. Observation of metastable Aβ amyloid protofibrils by atomic force microscopy , 1997 .
[286] K. Jacobson,et al. Small molecule blockers of the Alzheimer Aβ calcium channel potently protect neurons from Aβ cytotoxicity , 2009, Proceedings of the National Academy of Sciences.
[287] D. Selkoe,et al. Targeting of cell-surface β-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments , 1992, Nature.
[288] K. Kosik. The neuronal microRNA system , 2006, Nature Reviews Neuroscience.
[289] D. Avramopoulos. Genetics of Alzheimer's disease: recent advances , 2009, Genome Medicine.
[290] F. Grüninger. Invited review: Drug development for tauopathies , 2015, Neuropathology and applied neurobiology.
[291] Chi Li,et al. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[292] W. K. Cullen,et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.
[293] F. Panza,et al. Towards disease-modifying treatment of Alzheimer's disease: drugs targeting beta-amyloid. , 2010, Current Alzheimer research.
[294] R. Castellani,et al. Alzheimer disease. , 2010, Disease-a-month : DM.
[295] R. Ye,et al. Microglial Aβ Receptors in Alzheimer’s Disease , 2014, Cellular and Molecular Neurobiology.
[296] B. Zlokovic. Cerebrovascular transport of Alzheimer's amyloid beta and apolipoproteins J and E: possible anti-amyloidogenic role of the blood-brain barrier. , 1996, Life sciences.
[297] Wickliffe C Abraham,et al. Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory , 2003, Progress in Neurobiology.
[298] D. Bertrand,et al. EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors , 2012, Neuropharmacology.
[299] S. Müller,et al. Multiple Assembly Pathways Underlie Amyloid-β Fibril Polymorphisms , 2005 .
[300] H. Lee,et al. Increased expression of the receptor for advanced glycation end products in neurons and astrocytes in a triple transgenic mouse model of Alzheimer's disease , 2014, Experimental & Molecular Medicine.
[301] F. Checler,et al. Presenilin-Dependent Transcriptional Control of the Aβ-Degrading Enzyme Neprilysin by Intracellular Domains of βAPP and APLP , 2005, Neuron.
[302] C. Masters,et al. Iron-Export Ferroxidase Activity of β-Amyloid Precursor Protein Is Inhibited by Zinc in Alzheimer's Disease , 2010, Cell.
[303] D. Teplow,et al. Amyloid beta-protein monomer folding: free-energy surfaces reveal alloform-specific differences. , 2008, Journal of molecular biology.
[304] John W. Gilbert,et al. Cellular Prion Protein Mediates Impairment of Synaptic Plasticity by Amyloid-β Oligomers , 2009, Nature.
[305] Ann Marie Schmidt,et al. RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain , 2003, Nature Medicine.
[306] J. Verheijen,et al. The Migration of Human Smooth Muscle Cells In Vitro Is Mediated by Plasminogen Activation and Can Be Inhibited by α2-Macroglobulin Receptor Associated Protein , 1997, Thrombosis and Haemostasis.
[307] T. Benzinger,et al. Two-Dimensional Structure of β-Amyloid(10−35) Fibrils† , 2000 .
[308] D. Westaway,et al. In vivo reduction of amyloid-β by a mutant copper transporter , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[309] A. Tomasselli,et al. Changes in γ-secretase activity and specificity caused by the introduction of consensus aspartyl protease active motif in Presenilin 1 , 2008, Molecular Neurodegeneration.
[310] A. Igarashi,et al. Angiotensin-converting Enzyme Degrades Alzheimer Amyloid β-Peptide (Aβ); Retards Aβ Aggregation, Deposition, Fibril Formation; and Inhibits Cytotoxicity* , 2001, The Journal of Biological Chemistry.
[311] Giuseppe Sorrentino,et al. Solution structure of amyloid beta-peptide (25-35) in different media. , 2004, Journal of medicinal chemistry.
[312] R. Deane,et al. Neurovascular Pathways and Alzheimer Amyloid β‐peptide , 2005, Brain pathology.
[313] P. Mantegazza,et al. Therapeutic effect of CHF5074, a new γ-secretase modulator, in a mouse model of scrapie , 2012, Prion.
[314] D. Selkoe,et al. Amyloid β-peptide is produced by cultured cells during normal metabolism , 1992, Nature.
[315] R. Wetzel,et al. An intersheet packing interaction in A beta fibrils mapped by disulfide cross-linking. , 2004, Biochemistry.
[316] E. Masliah,et al. Neprilysin-2 is an important β-amyloid degrading enzyme. , 2011, The American journal of pathology.
[317] R. Deane,et al. Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease. , 2007, Current Alzheimer research.
[318] T. Wisniewski,et al. Brain uptake of circulating apolipoproteins J and E complexed to Alzheimer's amyloid beta. , 1994, Biochemical and biophysical research communications.
[319] R. Trullas,et al. Amyloid beta oligomers induce Ca2+ dysregulation and neuronal death through activation of ionotropic glutamate receptors. , 2010, Cell calcium.
[320] Y. Auberson,et al. Endoplasmic reticulum stress occurs downstream of GluN2B subunit of N‐methyl‐D‐aspartate receptor in mature hippocampal cultures treated with amyloid‐β oligomers , 2012, Aging cell.
[321] B. Hyman,et al. The Alzheimer's Disease-Associated Amyloid β-Protein Is an Antimicrobial Peptide , 2010, PloS one.
[322] R. Wetzel,et al. Abeta amyloid fibrils possess a core structure highly resistant to hydrogen exchange. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[323] Ralf Langen,et al. Structural Organization of α-Synuclein Fibrils Studied by Site-directed Spin Labeling* , 2003, Journal of Biological Chemistry.
[324] F. Panza,et al. Towards Disease-Modifying Treatment of Alzheimers Disease: Drugs Targeting β -Amyloid , 2009 .
[325] J. Hardy,et al. The amyloid hypothesis of Alzheimer's disease at 25 years , 2016, EMBO molecular medicine.
[326] D. Kirschner,et al. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. , 1990, Science.
[327] D. Small,et al. Regulation of APP cleavage by alpha-, beta- and gamma-secretases. , 2000, FEBS letters.
[328] R. Tanzi,et al. Clearance of Alzheimer's Aβ Peptide The Many Roads to Perdition , 2004, Neuron.
[329] A. Fagan,et al. Human and Murine ApoE Markedly Alters Aβ Metabolism before and after Plaque Formation in a Mouse Model of Alzheimer's Disease , 2002, Neurobiology of Disease.
[330] T. Wisniewski,et al. Reversion of prion protein conformational changes by synthetic b-sheet breaker peptides , 2000, The Lancet.
[331] B. de Strooper,et al. Attack on amyloid , 2003, EMBO reports.
[332] R. Ye,et al. The chemerin receptor CMKLR1 is a functional receptor for amyloid-β peptide. , 2015, Journal of Alzheimer's disease : JAD.
[333] R. Deane,et al. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. , 2004, Neuron.
[334] H. Levine. Alzheimer’s β-peptide oligomer formation at physiologic concentrations , 2004 .
[335] Mark S. Shearman,et al. Amyloid-β Hypothesis of Alzheimer’s Disease , 1998 .
[336] I. Kurochkin,et al. Alzheimer's β‐amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme , 1994, FEBS letters.
[337] E. Matsubara,et al. Isoform‐Specific Effects of Apolipoproteins E2, E3, and E4 on Cerebral Capillary Sequestration and Blood‐Brain Barrier Transport of Circulating Alzheimer's Amyloid β , 1997, Journal of neurochemistry.
[338] G. Westmeyer,et al. Identification of a β-Secretase Activity, Which Truncates Amyloid β-Peptide after Its Presenilin-dependent Generation* , 2003, The Journal of Biological Chemistry.
[339] J. Hoh,et al. Growth of beta-amyloid(1-40) protofibrils by monomer elongation and lateral association. Characterization of distinct products by light scattering and atomic force microscopy. , 2002, Biochemistry.
[340] D. Butterfield,et al. Enhancement of β‐Amyloid Peptide Aβ(1–40)‐Mediated Neurotoxicity by Glutamine Synthetase , 1995 .
[341] W. Klein,et al. Aβ Oligomers Induce Neuronal Oxidative Stress through an N-Methyl-D-aspartate Receptor-dependent Mechanism That Is Blocked by the Alzheimer Drug Memantine* , 2007, Journal of Biological Chemistry.
[342] Y. Nishiyama,et al. Exceptional Amyloid β Peptide Hydrolyzing Activity of Nonphysiological Immunoglobulin Variable Domain Scaffolds* , 2008, Journal of Biological Chemistry.
[343] K. Reymann,et al. Early neuronal dysfunction by amyloid β oligomers depends on activation of NR2B-containing NMDA receptors , 2011, Neurobiology of Aging.
[344] S. Paul,et al. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-β peptides , 2004, Nature Medicine.
[345] H. Levine. Alzheimer's beta-peptide oligomer formation at physiologic concentrations. , 2004, Analytical biochemistry.
[346] H. Emonard,et al. LRP-1: A Checkpoint for the Extracellular Matrix Proteolysis , 2013, BioMed research international.
[347] P. Hajduk,et al. Structural characterization of a soluble amyloid beta-peptide oligomer. , 2009, Biochemistry.
[348] Y. Nishiyama,et al. Metal-dependent amyloid β-degrading catalytic antibody construct. , 2014, Journal of biotechnology.
[349] S. Pimplikar,et al. APP Intracellular Domain Impairs Adult Neurogenesis in Transgenic Mice by Inducing Neuroinflammation , 2010, PloS one.
[350] D. Teplow,et al. Identification of antihypertensive drugs which inhibit amyloid-beta protein oligomerization. , 2009, Journal of Alzheimer's disease : JAD.
[351] Yan Yan,et al. Alzheimer’s disease-associated mutations increase amyloid precursor protein resistance to γ-secretase cleavage and the Aβ42/Aβ40 ratio , 2016, Cell Discovery.
[352] J. Quinn,et al. L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer's disease , 2011, Neurobiology of Disease.
[353] C. Patlak,et al. Fate of Cerebrospinal Fluid‐Borne Amyloid β‐Peptide: Rapid Clearance into Blood and Appreciable Accumulation by Cerebral Arteries , 1996, Journal of neurochemistry.
[354] K. Tanzawa,et al. Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[355] M. Sabbagh,et al. Effect of TTP488 in patients with mild to moderate Alzheimer’s disease , 2014, BMC Neurology.
[356] Peipei Wang,et al. A glucan isolated from flowers of Lonicera japonica Thunb. inhibits aggregation and neurotoxicity of Aβ42. , 2014, Carbohydrate polymers.
[357] J. D. Robertson,et al. Copper, iron and zinc in Alzheimer's disease senile plaques , 1998, Journal of the Neurological Sciences.
[358] Gerd Buntkowsky,et al. Solid State NMR Reveals a pH-dependent Antiparallel β-Sheet Registry in Fibrils Formed by a β-Amyloid Peptide , 2004 .
[359] L S Honig,et al. Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. , 2003, Neurology.
[360] Lijuan Wu,et al. Subcutaneous administration of liraglutide ameliorates learning and memory impairment by modulating tau hyperphosphorylation via the glycogen synthase kinase-3β pathway in an amyloid β protein induced alzheimer disease mouse model. , 2016, European journal of pharmacology.
[361] Lin Hong,et al. Subsite Specificity of Memapsin 2 (β-Secretase): Implications for Inhibitor Design† , 2001 .
[362] M. Desco,et al. Resveratrol: un polifenol neuroprotector de la dieta mediterránea , 2012 .
[363] F. Xie,et al. Inhibition of amyloid-β aggregation by coumarin analogs can be manipulated by functionalization of the aromatic center. , 2011, Bioorganic & medicinal chemistry.
[364] C. Pereira,et al. Protein Interactions between CD2 and Lck Are Required for the Lipid Raft Distribution of CD21 , 2008, The Journal of Immunology.
[365] M. Parker,et al. Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies , 2015, Scientific Reports.
[366] R. Wetzel,et al. Conformational Abs recognizing a generic amyloid fibril epitope , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[367] Kang Hu,et al. High-Level Neuronal Expression of Aβ1–42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation , 2000, The Journal of Neuroscience.
[368] J. Monti,et al. Gallotannins and Tannic Acid: First Chemical Syntheses and In Vitro Inhibitory Activity on Alzheimer's Amyloid β-Peptide Aggregation. , 2015, Angewandte Chemie.
[369] M. Ball,et al. Proteolysis of A beta peptide from Alzheimer disease brain by gelatinase A. , 1994, Biochemical and biophysical research communications.
[370] K. Aterman. A historical note on the iodine-sulphuric acid reaction of amyloid , 1976, Histochemistry.